News Center

News Center

News Center

First Patient Dosed in Phase I/IIa Study of DualityBio’s BDCA2-Targeting ADC DB-2304 for Systemic Lupus Erythematosus

2025-04-15

DualityBio (9606.HK) Officially Lists on Hong Kong Stock Exchange, Embarking on a New Chapter
2025-04-07

Duality Bio Appoints Hua Mu as Global Chief Medical Officer
2025-01-13

Voluntary Annuoncement Cooperation Between 3SBio Inc. And Duality Biol Ogics In Respect Of Her2 Adc Drug
2025-01-08

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate
2024-12-31

Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene
2024-12-06

Duality Biologics and BioNTech Presented Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors at the ESMO Asia Congress 2024

«
1
2
3
4
»

Scan the code to follow DualityBio official wechat

Phone：021-2601 8730

Address：Full floor, 11th floor, tower a, Datang International Plaza,China

Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai